The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/200. Please see abreview for further details.
Use at an assay dependent concentration.
1/500 - 1/1000. Detects a band of approximately 61 kDa (predicted molecular weight: 61 kDa).
FunctionRegulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
Tissue specificityHigh expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
Involvement in diseaseDefects in CHEK2 are associated with Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]; a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53/TP53. Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Defects in CHEK2 are found in some patients with osteogenic sarcoma (OSRC) [MIM:259500].
Sequence similaritiesBelongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily. Contains 1 FHA domain. Contains 1 protein kinase domain.
Post-translational modificationsPhosphorylated by PLK4.
Cellular localizationNucleus; Nucleus. Isoform 10 is present throughout the cell and Nucleus > PML body. Nucleus > nucleoplasm. Recruited into PML bodies together with TP53.
Lane 1 : extracts from Jurkat cells Lane 2 : extracts from Jurkat cells incubated with immunizing peptide
Predicted band size : 61 kDa Observed band size : 61 kDa
Immunocytochemistry/ Immunofluorescence - Chk2 antibody (ab47433)This image is courtesy of an Abreview submitted by Dr Kirk McManus
ab47433 (1/200) detecting Chk2 in HeLa cells in conjunction with a goat anti-mouse secondary antibody conjugated to Cy3 (red). Cells were counterstained with DAPI in order to highlight the nucleus (blue), treated with Bleomycin and incubated with an antibody against Histone H2AX in order to create and expose DNA double strand breaks (green). Please refer to abreviews for further details.
ab47433 at 1/100 dilution staining Chk2 in human breast carcinoma tissue section by Immunohistochemistry (Formalin/ PFA fixed paraffin embedded tissue sections). Right image show staining with ab47433 after incubation with specific peptide and left image show staining with untreated antibody.
References for Anti-Chk2 antibody (ab47433)
This product has been referenced in:
Abdel-Fatah TM et al. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. Neoplasia16:982-91 (2014).
Read more (PubMed: 25425972) »
Singh KK et al. BRCA2 Protein Deficiency Exaggerates Doxorubicin-induced Cardiomyocyte Apoptosis and Cardiac Failure. J Biol Chem287:6604-14 (2012).
Read more (PubMed: 22157755) »